Based on available clinical, local resource utilization, and unit cost data, the present economic evaluation suggests that lorlatinib, a potent, brain-penetrant, targeted therapy covering the unmet medical need of patients with advanced, ALK-positive NSCLC who have progressed after treatment with at least one second-generation TKI, was found to be a cost-effective option over P-ChT in Greece. This evidence concerns the gene ALK and non-small cell lung carcinoma.